Somnolence with Trintellix (Vortioxetine)
Yes, somnolence (sleepiness) has been reported with Trintellix, particularly in overdose situations, though it is not a commonly reported adverse effect at therapeutic doses.
Evidence from FDA Drug Label
The FDA label for Trintellix explicitly documents somnolence as an adverse event in overdose scenarios. In overdose cases ranging from 40-75 mg (2-3.75 times the maximum recommended daily dose), somnolence was specifically reported among the adverse effects, along with nausea, dizziness, diarrhea, abdominal discomfort, generalized pruritus, and flushing 1.
Therapeutic Dose Context
At standard therapeutic doses (5-20 mg/day), the incidence of somnolence with vortioxetine appears relatively low compared to other antidepressants. Research indicates that vortioxetine has a low incidence of sleep disruption, possibly due to its unique receptor modulation profile 2.
In controlled trials, the general adverse event profile of second-generation antidepressants includes somnolence as one of the commonly reported effects across the class 3. However, specific data for vortioxetine at therapeutic doses shows:
- Insomnia-related adverse events occurred in only 2.0-5.1% of patients on vortioxetine (5-20 mg/day) versus 4.0% on placebo 4
- The drug actually demonstrated improvements in sleep quality measures (Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and Insomnia Severity Index) in patients with major depressive disorder over 8 weeks of treatment 5
Clinical Implications
The paradox here is important: While somnolence can occur with vortioxetine (especially in overdose), the drug generally improves sleep disturbances associated with depression rather than causing excessive daytime sleepiness at therapeutic doses. The multimodal mechanism of action—combining serotonin reuptake inhibition with modulation of multiple 5-HT receptor subtypes—likely accounts for this favorable sleep profile 2, 6.
Key Caveats:
- Dose-dependent effects: Higher doses may carry increased risk
- Individual variation: Some patients may experience somnolence even at therapeutic doses
- Context matters: Overdose situations clearly increase somnolence risk
- Monitor particularly in elderly patients or those on multiple CNS-active medications
The overall tolerability profile suggests vortioxetine is less likely to cause problematic somnolence compared to medications like trazodone or mirtazapine, which have higher rates of this adverse effect 3.